Australian regulator flags rare but severe eye disorder risk with GLP-1 weight-loss drugs

Patients using GLP-1 medications face potential risk of rare but severe eye disorders that could result in blindness or significant vision loss.

As GLP-1 medications like Ozempic have reshaped the global conversation around weight loss and diabetes management, Australia's medicines regulator has issued a formal warning linking these widely-used drugs to a rare but potentially blinding eye disorder. The alert arrives at a moment when millions of patients worldwide have come to rely on these treatments, and when legal cases in the United States are already pressing the question of whether their risks were fully understood before they became blockbuster therapies. It is a reminder, as old as medicine itself, that the full consequences of

Australian regulator flags rare but severe eye disorder risk with GLP-1 weight-loss drugs

Cobertura Relacionada

Receba o Register no seu e-mail